Article Text

Download PDFPDF

Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT)
  1. Anne C Seagrove1,
  2. M Fasihul Alam2,
  3. Laith Alrubaiy1,
  4. Wai-Yee Cheung1,
  5. Clare Clement1,
  6. David Cohen2,
  7. Michelle Grey1,
  8. Mike Hilton1,
  9. Hayley Hutchings1,
  10. Jayne Morgan1,
  11. Frances Rapport1,
  12. Stephen E Roberts1,
  13. Daphne Russell1,
  14. Ian Russell1,
  15. Linzi Thomas3,
  16. Kymberley Thorne1,
  17. Alan Watkins1,
  18. John G Williams1
  1. 1College of Medicine, Swansea University, Singleton Park, Swansea, UK
  2. 2Health Economics and Policy Research Unit, University of South Wales, Pontypridd, UK
  3. 3Abertawe Bro Morgannwg University Health Board, Singleton Hospital, Swansea, UK
  1. Correspondence to Dr Anne Seagrove; a.c.seagrove{at}


Introduction Many patients with ulcerative colitis (UC) present with acute exacerbations needing hospital admission. Treatment includes intravenous steroids but up to 40% of patients do not respond and require emergency colectomy. Mortality following emergency colectomy has fallen, but 10% of patients still die within 3 months of surgery. Infliximab and ciclosporin, both immunosuppressive drugs, offer hope for treating steroid-resistant UC as there is evidence of their short-term effectiveness. As there is little long-term evidence, this pragmatic randomised trial, known as Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: a Trial (CONSTRUCT), aims to compare the clinical and cost-effectiveness of infliximab and ciclosporin for steroid-resistant UC.

Methods and analysis Between May 2010 and February 2013, 52 UK centres recruited 270 patients admitted with acute severe UC who failed to respond to intravenous steroids but did not need surgery. We allocated them at random in equal proportions between infliximab and ciclosporin.The primary clinical outcome measure is quality-adjusted survival, that is survival weighted by Crohn's and Colitis Questionnaire (CCQ) participants’ scores, analysed by Cox regression. Secondary outcome measures include: the CCQ—an extension of the validated but community-focused UK Inflammatory Bowel Disease Questionnaire (IBDQ) to include patients with acute severe colitis and stoma; two general quality of life measures—EQ-5D and SF-12; mortality; survival weighted by EQ-5D; emergency and planned colectomies; readmissions; incidence of adverse events including malignancies, serious infections and renal disorders; disease activity; National Health Service (NHS) costs and patient-borne costs. Interviews investigate participants’ views on therapies for acute severe UC and healthcare professionals’ views on the two drugs and their administration.

Ethics and dissemination The Research Ethics Committee for Wales has given ethical approval (Ref. 08/MRE09/42); each participating Trust or Health Board has given NHS Reseach & Development approval. We plan to present trial findings at international and national conferences and publish in high-impact peer-reviewed journals.

Trial registration number ISRCTN: 22663589; EudraCT number: 2008-001968-36

  • Ulcerative colitis
  • Acute severe
  • Steroid refractory
  • Ciclosporin
  • Infliximab
  • Randomised controlled trial

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.